KLK3 and prostate carcinoma: Genistein has also been reported to significantly reduce matrix metalloproteinase type 2 (MMP-2) expression and serum prostate-specific antigen (PSA) concentrations in prostate cancer patients treated with ADT, suggesting that genistein may combat prostate cancer by affecting protease activity and reducing different markers of prostate cancer progression in humans (14).